News/Events
Subscribe to get latest news
News
Flamingo Therapeutics Announces Poster Presentation on the Immune-Modulatory Effects of Danvatirsen at the American Association for Cancer Research (AACR) Annual Meeting
Flamingo Therapeutics (“Flamingo”) today announced that an abstract has been accepted for presentation at the American Association for Cancer Research (AACR) annual meeting being held in Chicago, IL from April 25-30, 2025.
Flamingo Therapeutics Announces Participation in Upcoming Investor Conferences
Flamingo Therapeutics (“Flamingo”) announced today its participation in the following upcoming investor conferences:
Flamingo Therapeutics Announces Poster Presentation on AML Phase 1 IIT Study at ASH 2024
Flamingo Therapeutics ("Flamingo") today announced that an abstract has been selected for presentation at the 66th Annual ASH Annual Meeting and Exposition, being held in San Diego, CA from December 7-9, 2024.
Flamingo Therapeutics Announces Oral Presentation at AACR Special Conference in Cancer Research on RNAs as Drivers, Targets, and Therapeutics in Cancer
Flamingo Therapeutics (“Flamingo”) today announced an oral presentation at the AACR Special Conference in Cancer Research, RNAs as Drivers, Targets, and Therapeutics in Cancer, being held in Seattle, Washington from November 14-17, 2024.
Flamingo Therapeutics Announces Participation in Upcoming Investor Conferences
Flamingo Therapeutics (“Flamingo”) announced today its participation in the following upcoming investor conferences:
Flamingo Therapeutics Announces First Patients Dosed in the United Kingdom and Korea in ongoing Phase II PEMDA-HN Study for Head and Neck Squamous Cell Carcinoma (HNSCC)
Flamingo Therapeutics (“Flamingo”) today announced that the PEMDA-HN trial has expanded beyond the United States into the UK and Korea.
Media
Can Cancer Be Treated by Changing Its Cells?
In 2017, Karen Kostroff, a renowned oncology surgeon at Northwell Health in the New York Metropolitan area added a new talking point ...
The dark matter of the genome: Flamingo Therapeutics taps potential of mysterious RNA for cancer therapies
Flamingo Therapeutics was born out of a collaboration between three partners in Flanders – VIB, UGent and KU Leuven – and the University of Michigan ...
Leuvense biotechstarter mikt op nieuwe kankertherapieën
Flamingo werd vorig jaar opgericht als spin-off van het Vlaams Instituut voor Biotechnologie (VIB), de KU Leuven en UGent, maar opereerde ...
Ionis collaborator Flamingo is ready to take flight with 3 antisense drugs in the clinic and mysterious RNA in its sights
As the biggest name in antisense technology, Ionis has long focused on testing the interplay between oligonucleotides and RNA for therapeutic effect ...